Stacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma.
Stacey Stein, MD
Advertisement
Stacey Stein, MD, is an associate professor of internal medicine and the assistant medical director of the Clinical Trials Office at Yale School of Medicine.
Articles by Stacey Stein, MD
Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
